Cargando…

A Population-based Study of the Effectiveness of Stereotactic Ablative Radiotherapy Versus Conventional Fractionated Radiotherapy for Clinical Stage I Non-small Cell Lung Cancer Patients

BACKGROUND: Stereotactic ablative radiotherapy (SABR) is a promising option for non-operated early-stage non-small cell lung cancer (NSCLC) compared to conventional fractionated radiotherapy (CFRT). However, results from conclusive randomized controlled trials are not yet available. The aim of our s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tu, Chih-Yen, Hsia, Te-Chun, Fang, Hsin-Yuan, Liang, Ji-An, Yang, Su-Tso, Li, Chia-Chin, Chien, Chun-Ru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043889/ https://www.ncbi.nlm.nih.gov/pubmed/30018522 http://dx.doi.org/10.1515/raon-2017-0058

Ejemplares similares

Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the treatment of hepatocellular carcinoma with portal vein invasion: a retrospective analysis
por: Yang, Jen-Fu, et al.
Publicado: (2019)

Stereotactic ablative body radiotherapy versus conventionally fractionated radiotherapy for early stage large cell neuroendocrine carcinoma of the lung
por: Wegner, Rodney E, et al.
Publicado: (2020)

Effectiveness of image‐guided radiotherapy for locally advanced lung cancer patients treated with definitive concurrent chemoradiotherapy
por: Liang, Ji‐An, et al.
Publicado: (2020)

Stereotactic Ablative Radiotherapy Fractionation for Hepatocellular Carcinoma in the United States
por: Sheth, Niki, et al.
Publicado: (2020)

Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization
por: Lee, Hsin-Lun, et al.
Publicado: (2019)

Effects of two different radiotherapies for craniopharyngiomas using stereotactic radiosurgery/ stereotactic radiotherapy or fractionated stereotactic radiotherapy
por: Kamogawa, Misaki, et al.
Publicado: (2022)

Cost-effectiveness of stereotactic body radiotherapy versus conventional fractionated radiotherapy for medically inoperable, early-stage non-small cell lung cancer
por: Sun, Hui, et al.
Publicado: (2023)

Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression
por: Ho, Chin-Beng, et al.
Publicado: (2023)

Advances in Radiobiology of Stereotactic Ablative Radiotherapy
por: Qiu, Bin, et al.
Publicado: (2020)

The Role of Conventionally Fractionated Radiotherapy and Stereotactic Radiotherapy in the Treatment of Carcinoid Tumors and Large-Cell Neuroendocrine Cancer of the Lung
por: Bilski, Mateusz, et al.
Publicado: (2021)

Doses, fractionations, constraints for stereotactic radiotherapy
por: Borghesi, Simona, et al.
Publicado: (2022)

Feasibility of Proton Transmission-Beam Stereotactic Ablative Radiotherapy versus Photon Stereotactic Ablative Radiotherapy for Lung Tumors: A Dosimetric and Feasibility Study
por: Mou, Benjamin, et al.
Publicado: (2014)

Dosimetric comparison of different treatment modalities for stereotactic radiotherapy
por: Hsu, Shih-Ming, et al.
Publicado: (2017)

Whole Pelvic Radiotherapy With Stereotactic Body Radiotherapy Boost vs. Conventionally Fractionated Radiotherapy for Patients With High or Very High-Risk Prostate Cancer
por: Wang, Shih-Chang, et al.
Publicado: (2020)

Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma
por: Webking, Samantha, et al.
Publicado: (2023)

The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology
por: Finkelstein, Steven Eric, et al.
Publicado: (2011)

Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver
por: Kim, Myungsoo, et al.
Publicado: (2014)

Adrenal oligometastasis cured with stereotactic ablative radiotherapy
por: Malone, Julia, et al.
Publicado: (2020)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

Prognostic Significance of Apparent Diffusion Coefficient in Hepatocellular Carcinoma Patients treated with Stereotactic Ablative Radiotherapy
por: Lo, Cheng-Hsiang, et al.
Publicado: (2019)

Comparison of local ablative therapies, including radiofrequency ablation, microwave ablation, stereotactic ablative radiotherapy, and particle radiotherapy, for inoperable hepatocellular carcinoma: a systematic review and meta-analysis
por: Cheng, Po-Lung, et al.
Publicado: (2023)

Establishing the Role of Stereotactic Ablative Body Radiotherapy in Early-Stage Breast Cancer
por: Barry, Aisling, et al.
Publicado: (2018)

Fractionated stereotactic radiotherapy in the treatment of pituitary macroadenomas
por: Elhateer, H., et al.
Publicado: (2008)

Fractionated stereotactic radiotherapy for pediatric patients with retinoblastoma
por: Higgins, Patrick D., et al.
Publicado: (2006)

Management of Chordoma and Chondrosarcoma with Fractionated Stereotactic Radiotherapy
por: Vasudevan, Harish N., et al.
Publicado: (2017)

The Quest for Optimal Fractionation Schedules in Stereotactic Radiotherapy
por: Shibamoto, Yuta, et al.
Publicado: (2020)

Survival and prognostic factors for patients with advanced hepatocellular carcinoma after stereotactic ablative radiotherapy
por: Lo, Cheng-Hsiang, et al.
Publicado: (2017)

Comparative Study of Hypo-Fractionated Radiotherapy Versus Conventional Radiotherapy in Breast Cancer
por: Narwariya, Abhinav, et al.
Publicado: (2022)

Prospective Randomized Phase II Study of Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionated Radiotherapy (CFRT) for Chinese Patients with Early-Stage Localized Prostate Cancer †
por: Poon, Darren M. C., et al.
Publicado: (2021)

Organizing pneumonia after stereotactic ablative radiotherapy of the lung
por: Murai, Taro, et al.
Publicado: (2012)

Technical know‐how in stereotactic ablative radiotherapy (SABR)
por: Lo, Simon S., et al.
Publicado: (2016)

Commissioning and initial stereotactic ablative radiotherapy experience with Vero
por: Solberg, Timothy D., et al.
Publicado: (2014)

Stereotactic ablative body radiotherapy in patients with prostate cancer
por: Loblaw, Andrew, et al.
Publicado: (2018)

Feasibility of split-course stereotactic ablative radiotherapy for oligometastases
por: Paik, Eun Kyung, et al.
Publicado: (2018)

Stereotactic ablative radiotherapy in patients with refractory ventricular tachyarrhythmia
por: Molon, Giulio, et al.
Publicado: (2022)

Extracranial doses in stereotactic and conventional radiotherapy for pituitary adenomas
por: Ram, Thomas Samuel, et al.
Publicado: (2006)

Comparative effectiveness of concurrent chemoradiotherapy versus EGFR‐tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR
por: Hsia, Te‐Chun, et al.
Publicado: (2018)

Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer
por: Phak, Jeong Hoon, et al.
Publicado: (2016)

Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy
por: Ma, Ting Martin, et al.
Publicado: (2020)

Stereotactic ablative radiotherapy for early-stage lung cancer following double lung transplantation
por: Chen, Hanbo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n0ckuhl55feb0s4s9pdbfjb460